Adaptimmune Therapeutics plc

ADAP05 Dec 2024
Healthcare
$0.69
+0.00 (+0.23%)
Lowest Today
$0.66
Highest Today
$0.7
Today’s Open
$0.69
Prev. Close
$0.7
52 Week High
$2.05
52 Week Low
$0.43
To Invest in Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc

Healthcare
ADAP05 Dec 2024
+0.00 (+0.23%)
1M
3M
6M
1Y
5Y
Low
$0.66
Day’s Range
High
$0.7
0.66
52 Week Low
$0.43
52-Week Range
52 Week High
$2.05
0.43
1 Day
-
1 Week
-0.3%
1 month return
-14.51%
3 month return
-40.39%
6 month return
-30.6%
1 Year return
+34.03%
3 Years return
-80.62%
5 Years return
-41.39%
10 Years return
-
Institutional Holdings
Matrix Capital Management Company, LLC
14.73
EcoR1 Capital, LLC
10.71
NEA Management Company, LLC
6.67
Baillie Gifford & Co Limited.
6.56
Long Focus Capital Management, LLC
5.2
Partner Fund Management LP
3.91
Edinburgh Worldwide Ord
2.91

Market Status

Fundamentals
Market Cap
185.05 mln
PB Ratio
2.31
PE Ratio
0
Enterprise Value
73.46 mln
Total Assets
282.62 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Organisation
Adaptimmune Therapeutics plc
Employees
449
Industry
Biotechnology
CEO
Mr. Adrian G.  Rawcliffe
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities